scholarly journals Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review

2021 ◽  
Vol 69 (4) ◽  
pp. 547-560
Author(s):  
Merve Akyol ◽  
Enes Çevik ◽  
Duygu Ucku ◽  
Cem Tanrıöver ◽  
Barış Afşar ◽  
...  
Keyword(s):  
Systematic Review ◽  
Kidney Transplant ◽  
Transplant Patients ◽  
Kidney Transplant Patients

scholarly journals Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 8 (4) ◽  
pp. 47
Author(s):  
Api Chewcharat ◽  
Narut Prasitlumkum ◽  
Charat Thongprayoon ◽  
Tarun Bathini ◽  
Juan Medaura ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Blood Pressure ◽  
Body Weight ◽  
Kidney Transplant ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Transplant Patients ◽  
Treatment Of Diabetes ◽  
Kidney Transplant Patients

Background: The objective of this systematic review was to evaluate the efficacy and safety profiles of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for treatment of diabetes mellitus (DM) among kidney transplant patients. Methods: We conducted electronic searches in Medline, Embase, Scopus, and Cochrane databases from inception through April 2020 to identify studies that investigated the efficacy and safety of SGLT-2 inhibitors in kidney transplant patients with DM. Study results were pooled and analyzed utilizing random-effects model. Results: Eight studies with 132 patients (baseline estimated glomerular filtration rate (eGFR) of 64.5 ± 19.9 mL/min/1.73 m2) treated with SGLT-2 inhibitors were included in our meta-analysis. SGLT-2 inhibitors demonstrated significantly lower hemoglobin A1c (HbA1c) (WMD = −0.56% [95%CI: −0.97, −0.16]; p = 0.007) and body weight (WMD = −2.16 kg [95%CI: −3.08, −1.24]; p < 0.001) at end of study compared to baseline level. There were no significant changes in eGFR, serum creatinine, urine protein creatinine ratio, and blood pressure. By subgroup analysis, empagliflozin demonstrated a significant reduction in body mass index (BMI) and body weight. Canagliflozin revealed a significant decrease in HbA1C and systolic blood pressure. In terms of safety profiles, fourteen patients had urinary tract infection. Only one had genital mycosis, one had acute kidney injury, and one had cellulitis. There were no reported cases of euglycemic ketoacidosis or acute rejection during the treatment. Conclusion: Among kidney transplant patients with excellent kidney function, SGLT-2 inhibitors for treatment of DM are effective in lowering HbA1C, reducing body weight, and preserving kidney function without reporting of serious adverse events, including euglycemic ketoacidosis and acute rejection.

Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel

2018 ◽  
Vol 4 (2) ◽  
pp. 153-162 ◽  
Author(s):  
Vital Hevia ◽  
Romain Boissier ◽  
Óscar Rodríguez-Faba ◽  
Claire Fraser-Taylor ◽  
Rhana Hassan-Zakri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Renal Transplantation ◽  
Kidney Transplant ◽  
Transplant Patients ◽  
Kidney Transplant Patients

scholarly journals Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

2020 ◽  
Vol 5 (2) ◽  
pp. 149-158 ◽  
Author(s):  
Sandhya Manohar ◽  
Charat Thongprayoon ◽  
Wisit Cheungpasitporn ◽  
Svetomir N. Markovic ◽  
Sandra M. Herrmann
Keyword(s):  
Systematic Review ◽  
Kidney Transplant ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Transplant Patients ◽  
Kidney Transplant Patients
Sign in / Sign up

Export Citation Format

Share Document